Amferia AB is pleased toannounce the appointment of two new board members, Randy Schwartz and NikolajSørensen, to help guide the company's next phase of global expansion. FollowingAmferia’s recent FDA De Novo approval, the company is actively preparing toaccelerate its commercial entry into the US market. The addition of these twoaccomplished leaders brings targeted expertise in wound care commercialization,advanced medical devices, and international life science strategy—providing apowerful foundation for Amferia's continued growth.
RandySchwartz is a senior healthcare executive and consultant with more than 40years of experience driving growth, innovation, and market leadership in themedical technology, wound care, and skin health industries. As Principal of MedMarket Consultants and GR Consulting Solutions, he advises start-up, emerging,and established healthcare companies on commercialization, market access,reimbursement, clinical strategy, business development, and global expansion.Previously, Randy held multiple executive leadership roles at Molnlycke HealthCare, including Global Vice President of Medical & Professional Affairs,Vice President of Marketing, and Global Marketing Director, where he helpedestablish the company as a global leader in advanced wound care. He hasextensive experience in strategic marketing, evidence development, productlaunches, M&A, and international market expansion, and currently serves onthe Board of the Wound Care Collaborative Community, an FDA-recognized collaborativecommunity focused on advancing innovation in wound care.
NikolajSørensen has established an impressive track record within the internationalpharmaceutical and healthcare sectors, holding premier leadership positionssuch as; Managing Director of Pfizer AB, Senior Management roles across PfizerInc., Management Consultant at the Boston Consulting Group, and presently servesas the President and CEO of Orexo AB. Today, he utilizes his deep expertise inglobal corporate strategy to serve on the boards of pioneering enterprises.Nikolaj’s extensive knowledge in pharmaceutical commercialization andinternational scaling will be important for Amferia’s scale-up journey in bothhuman and animal wound care.
TheAGM also chose to re-elect Agneta Edberg (chair), Professor Martin Andersson,Anders Husmark and Henrik Jansson.
